DUBLIN, Dec. 23, 2019 /PRNewswire/ — Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for Ubrelvy (ubrogepant) for the acute treatment of migraine with or without…Original Article
FDA Approves Ubrelvy (ubrogepant) for the Acute Treatment of Migraine
